Comparar métodos

	Sinonasal Outcome Test-22	Cuestionario de Calidad de Vida en Rinoconjuntivitis
Campo	Neumología	Neumología
Familia	Process / pipeline	Process / pipeline
Año de origen	2009	1996
Autor original	Claire Hopkins, King's College London	Elizabeth F. Juniper, McMaster University
Tipo	Self-report questionnaire	Self-report questionnaire
Fuente seminal	Hopkins, C., Gillett, S., Slack, R., Lund, V. J., & Browne, J. P. (2009). Psychometric validity of the 22-item Sinonasal Outcome Test. Clinical Otolaryngology, 34(5), 447-454.	Juniper, E. F., Guyatt, G. H., Streiner, D. L., & King, D. R. (1996). Clinical validation and responsiveness of three scales developed to measure the effect of allergic rhinitis on quality of life. Journal of Clinical Epidemiology, 49(3), 339-347.
Alias	SNOT-22, SNOT	RQLQ, Rhinoconjunctivitis QoL
Relacionados	5	5
Resumen	The SNOT-22 is a 22-item disease-specific quality-of-life questionnaire designed to assess sino-nasal symptoms and their functional impact on patients with chronic rhinosinusitis, nasal polyposis, and allied conditions. Developed by Hopkins and colleagues at King's College London in 2009, it has become the most widely used instrument for measuring sino-nasal disease burden in clinical trials and rhinological practice. The SNOT-22 provides rapid, patient-centered assessment of both nasal-specific symptoms (congestion, drainage, sneezing) and general health impacts (sleep, headache, concentration).	The RQLQ is a 28-item disease-specific quality-of-life instrument developed by Juniper and colleagues at McMaster University in 1996 to assess the impact of allergic rhinitis and allergic conjunctivitis on daily functioning. It captures symptom burden and activity limitation across seven domains: sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, activity limitation, and emotional function. The RQLQ is the preferred outcome measure in allergic rhinitis clinical trials and is widely used in allergy and immunology practice to track treatment response.